We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Galectin-3 Associated with Poor Prognosis in Cardiopathy Patients

By LabMedica International staff writers
Posted on 18 Jul 2013
The soluble β-galactoside-binding lectin, galectin-3, is elevated in a substantial portion of patients with heart failure, especially those with more severe disease and renal dysfunction.

Increased levels of circulating galectin-3 may reflect the severity of active myocardial remodeling and adverse outcome as galectin-3 regulates fibrogenesis, inflammation, tissue repair, and cell proliferation.

Image: Galectin-3 test kit (Photo courtesy of BG Medicine Inc.).
Image: Galectin-3 test kit (Photo courtesy of BG Medicine Inc.).

Scientists and cardiologists at the Veterans Administration Medical Center (Minneapolis, MN, USA) conducted a randomized, placebo-controlled, double-blind, multicenter trial that enrolled 5,010 patients with symptomatic heart failure (HF) to evaluate the efficacy of the angiotensin receptor blocker (ARB) valsartan. They measured galectin-3 and other biomarkers such as high-sensitivity C-reactive protein, high-sensitivity troponin, and B-type natriuretic peptide at three time points in a subpopulation of the trial patients. The time points were at baseline at 4 and 12 months after randomization.

Plasma samples from the patients were analyzed and galectin-3 was measured using an enzyme-linked immunosorbent assay (ELISA) (BG Medicine Inc.; Waltham, MA, USA). Galectin-3 levels at baseline ranged from 4.8 to 53 ng/mL. The median baseline galectin-3 level in 1,650 patients was 16.2 ng/mL, and levels increased significantly from baseline. At 4 months, the level increased by 1.0 ng/mL and by 12 months it had risen by 2.2 ng/mL. Each 1 ng/mL increase in galectin-3 was associated with an estimated 2.9% higher risk of mortality, 2.1% increased risk of first morbid event, and 2.2% greater risk of heart failure hospitalization.

The authors concluded that galectin-3 levels are elevated in a substantial proportion of patients with HF, particularly those with more severe HF and renal impairment. Median galectin-3 levels increased over time, and the magnitude of these serial increases was found to be independently and significantly associated with poorer HF outcomes. In patients with baseline galectin-3 levels below the median, use of valsartan was associated with a significant decrease in hospitalizations for heart failure. The study was published in the May 2013 issue of the European Journal of Heart Failure.

Related Links:
Veterans Administration Medical Center
BG Medicine Inc.


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Latest Clinical Chem. News

Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring

Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples

AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood



Sekisui Diagnostics UK Ltd.